Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (114)	5/14/2003 5:18:57 PM
From: tuck	Read Replies (1) \| Respond to of 510

Hi, Peter, Advion is a competitor in pretty indirect fashion. I had a gander at the Correlogic/Liotta/Petricoin patent. appft1.uspto.gov It covers mostly the pattern recognition, and the embodiments include data streams from SELDI, MALDI, SDS-PAGE, and SAGE. They can be combined in various ways. It would appear that NCI intends to use all methods, and some work better than others for certain samples. I don't know if CIPH tried to talk to the NCI guys about licensing, but in general, I'd like to see CIPH be a bit more forthcoming about what they intend to do in the clinical diagnostics area. The competition (Correlogic, CeMines, etc.) seems to be catching up. However, CIPH has license options with JHU and Eastern Virginia Medical (possibly others) for cancer biomarkers. So even though they may not get ovarian, they can compete in prostate cancer (Correlogic appears to have an interest there) via EVMS, and get a jump on breast cancer via JHU. I need to check out CIPH's software IP. Wondering if there's any potential conflict with Correlogic there. Cheers, Tuck